Akoya Biosciences
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$64.26M
-1.4
-1.12
$81.67M
205
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2021-04-16. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. The company offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.
emptyResult
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2021-04-16. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. The company offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.
Recently from Cashu
Akoya Biosciences Partners with Argonaut to Enhance Precision Medicine Diagnostics
Strategic Alliance to Advance Precision Medicine In a significant development within the life sciences sector, Akoya Biosciences, Inc. has partnered with Argonaut Manufacturing Services to enhance the…
Akoya Biosciences Partners with Argonaut for Enhanced IVD Development in Precision Medicine
Akoya Biosciences and Argonaut Manufacturing Services Forge Strategic Partnership for IVD Development In a significant development for precision medicine, Akoya Biosciences, Inc. has announced an expa…
Akoya Biosciences Merges with Quanterix to Revolutionize Biomarker Detection in Healthcare
Quanterix and Akoya Biosciences Unite to Transform Biomarker Detection Quanterix Corporation and Akoya Biosciences are set to reshape the landscape of disease detection through their recent all-stock…
Akoya Biosciences and Quanterix Merge to Transform Biomarker Detection Landscape
Quanterix and Akoya Biosciences Merger: A New Era in Biomarker Detection Quanterix Corporation has recently announced an all-stock merger with Akoya Biosciences, known as The Spatial Biology Company®.…